尼达利单抗(Nadunolimab) - 药物靶点：IL1RAP_在研适应症：肺结节，胰腺癌，晚期三阴性乳腺癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Nidanilimab、CAN-04、CAN04

靶点

IL1RAP

作用方式

抑制剂、刺激剂

作用机制

IL1RAP抑制剂(IL1RAP抑制剂)、Natural killer cells刺激剂(自然杀伤细胞刺激剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [2]

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 454033168L

来源: *****

Sequence Code 616720818H

来源: *****

关联

8

项与尼达利单抗相关的临床试验

NCT07284485

/ Recruiting临床2期IIT

A Phase 2 Trial of Nadunolimab for Current or Former Smokers With High-risk Lung Nodules.

The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.

开始日期2026-05-21

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+1]

NCT07281716

/ Recruiting临床1/2期IIT

A Phase 1b/2 Study of Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer. Phase 1b will assess dose-limiting toxicity (DLT), while Phase 2 will evaluate objective response rate (ORR), including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). Exploratory analyses will investigate immunomodulatory effects through tumor and peripheral blood studies, and treatment will continue every 3 weeks for up to 1 year or until disease progression.

开始日期2025-12-01

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+2]

NCT06548230

/ Recruiting临床1/2期

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

To evaluate safety and determine the recommended Phase II dose (RP2D). We hypothesize that targeting leukemia stem/progenitor cells (LSCs) with nadunolimab (IL1RAP antibody) alone or in combination with current therapies of azacitidine (HMA) and venetoclax (Bcl-2 inhibitor), is an effective treatment strategy for high-risk MDS and AML, and with a clinical trial we will establish the safety and the early efficacy of this approach.

开始日期2025-03-05

申办/合作机构-

100 项与尼达利单抗相关的临床结果

登录后查看更多信息

100 项与尼达利单抗相关的转化医学

登录后查看更多信息

100 项与尼达利单抗相关的专利（医药）

登录后查看更多信息

7

项与尼达利单抗相关的文献（医药）

2025-09-01·LUNG CANCER

Letter to the editor: Critical analysis of the CANFOUR trial on nadunolimab in advanced NSCLC

Letter

作者: Yang, Zongyu ; Liao, Songjie

2025-08-01·LUNG CANCER

Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet

Article

作者: Zvirbule, Zanete ; Magnusson, Susanne ; Thorsson, Lars ; Paz-Ares, Luis G ; Paulus, Astrid ; Garcia-Ribas, Ignacio ; Millrud, Camilla Rydberg ; Zemaitis, Marius ; Tersago, Dominique ; Sanfridson, Annika ; Losic, Nedjad ; Cicenas, Saulius

INTRODUCTION:

Interleukin-1 receptor accessory protein (IL1RAP), expressed in several tumors, is essential for IL-1α and IL-1β signaling which leads to tumor progression and treatment resistance. Nadunolimab, a fully humanized antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody, targets IL1RAP and blocks IL-1α/IL-1β signaling. Efficacy and safety of nadunolimab plus platinum-based doublet chemotherapies were assessed in patients with non-small cell lung cancer (NSCLC) (NCT03267316).

METHODS:

Patients with advanced NSCLC received nadunolimab plus platinum-based doublet chemotherapies in first-line or second-line post-pembrolizumab. Study objectives included the anti-tumor response, progression-free survival (PFS), overall survival (OS), levels of biomarkers in serum, and immunohistochemistry of baseline and on-treatment tumor biopsies.

RESULTS:

43 patients were enrolled, median age 64 years, 38 % female, and 43 % were treated in second-line post-pembrolizumab. Median PFS was 7.2 months (95 % CI 5.6-9.2), median OS was 13.7 months (95 % CI 11.1-18.3), and 1-year survival was 54 %. The greatest benefits were observed in 11 patients with non-squamous histology treated in second-line post-pembrolizumab: median OS 26.7 months, ORR 91 % including two complete responders (with distinct biomarker profiles), and 1-year survival 82 %. Biomarker analyses showed that patients in second-line post-pembrolizumab had an enhanced level of tumor-infiltrating immune cells compared to treatment naïve patients. Rates of Grade 3+ neutropenia, anemia, and thrombocytopenia were higher than previous reports of platinum-based doublet chemotherapies alone.

CONCLUSIONS:

Nadunolimab plus platinum-based doublet chemotherapies showed promising efficacy in advanced NSCLC, with the greatest benefit in patients with non-squamous histology treated in second line after relapsing on pembrolizumab treatment.

2025-06-01·INVESTIGATIONAL NEW DRUGS

Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors

Article

作者: Jimeno, Antonio ; Cohen, Roger B ; Millrud, Camilla Rydberg ; Sanfridson, Annika ; Hreno, Jennifer ; Garcia-Ribas, Ignacio ; Wallén-Öhman, Marie ; Sun, Lova

Summary:

Interleukin (IL)-1 signaling has an essential role in tumor progression and immunosuppression and is linked to acquired resistance to anti-PD-1/PD-L1 treatment. Nadunolimab is an IL1RAP (IL-1 receptor accessory protein)-targeting antibody that blocks IL-1α/IL-1β signaling and has enhanced antibody-dependent cellular cytotoxicity. We investigated the safety and preliminary efficacy of nadunolimab with pembrolizumab in patients with metastatic solid tumors who had progressed on previous checkpoint inhibitor treatment, suggesting acquired checkpoint inhibitor resistance (NCT04452214). This phase 1b trial enrolled patients with metastatic disease who had exhausted or declined standard-of-care alternatives. Patients received nadunolimab (5 mg/kg) and standard-dose pembrolizumab. The primary objective was to assess safety. Secondary objectives were anti-tumor response as per iRECIST, pharmacokinetics, and changes in immune mediators. Fifteen patients with stage IV cancer (head and neck squamous cell carcinoma, non-small cell lung cancer, melanoma) entered the trial. Grade ≥ 3 adverse events were reported for 7 patients (47%). There was one dose-limiting toxicity of febrile neutropenia. The most frequent grade ≥ 3 adverse event was dysphagia (two patients). Seven patients (47%) had reductions in target lesion size. Median iPFS was 3.4 months (95% CI 1.4–8.6). Median OS was 19.7 months (95% CI 4.3–28.7) with 67% 1-year survival. Survival was significantly longer in patients with higher baseline tumor infiltration of CD163 + macrophages and natural killer cells and in patients with reduced on-treatment circulating IL-6 levels or neutrophil-to-lymphocyte ratio. Nadunolimab with pembrolizumab had an acceptable safety profile, and prolonged disease control was observed in a subset of patients. The results support further development of nadunolimab in combination with checkpoint inhibitors.

62

项与尼达利单抗相关的新闻（医药）

2026-05-29

·BioSpace

Cantargia AB to Host Webcast Covering Rights Issue, Loan Agreement, and Strategic Priorities

LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company's press release on May 28, 2026, regarding the decision to conduct a rights issue in combination with a loan, Cantargia AB (Publ) ("Cantargia" or the "Company") invites shareholders, analysts and the press to a live web cast on June 1, 2026, at 4 pm CEST with details below. "This rights issue strengthens our ability to deliver on nadunolimab's full potential," said Hilde Steineger, CEO of Cantargia. "We can now move beyond our current preclinical commitments to capture emerging opportunities in PDAC, including combination strategies with RAS inhibitors, while at the same time advancing promising early signals in high‑risk MDS and AML. With this added financial flexibility, we are better positioned to build nadunolimab as a backbone therapy across both solid tumors and hematological malignancies, and to create long‑term value for patients and shareholders." The proceeds from the rights issue and loan agreement will strengthen Cantargia's financial position and enable expansion of its clinical development strategy beyond current commitments of the Company's preclinical research, supporting new opportunities in the evolving PDAC treatment landscape. Preclinical data indicate that IL1RAP targeting with nadunolimab complements RAS inhibition and may enhance anti-tumor activity, supporting planned combination study. The increased financial flexibility allows Cantargia to advance these opportunities while progressing existing preclinical programs, reinforcing nadunolimab's potential as a backbone therapy. Continued development in combination with gemcitabine and nab-paclitaxel is supported by encouraging efficacy and manageable safety. Cantargia has also reported promising early clinical data from an ongoing investigator-initiated Phase 1b/2a study at MD Anderson Cancer Center in MDS and AML, where IL1RAP is overexpressed. In the high-risk MDS cohort, all five evaluable patients achieved complete remission in Phase 1b, based on early but notable data. The study is now advancing into Phase 2a, expected to enroll approximately 40 patients. These results expand nadunolimab's clinical potential into hematology and, supported by the strengthened financial position, enable further development planning in MDS as a significant long-term opportunity for the Company. Participants who wish to join the audio cast, please use the link below. Via the web session you will be able to ask written questions. Webcast: If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. There will be an opportunity to ask questions verbally via the teleconference: For further information, please contact Hilde Steineger, CEO Telephone: +46 (0)46-275 62 60 E-mail: info@cantargia.com About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . Attachments Cantargia AB to Host Webcast covering Rights Issue, Loan Agreement, and Strategic Priorities SOURCE: Cantargia View the original press release on ACCESS Newswire

2026-05-22

·搜狐新闻

【最新消息】2026年MDS新药进展点燃生存希望，有望100%完全缓解！

近年来，MDS的新药研发迎来了“爆发期”，从低危到高危，从缓解症状到追求深度缓解，一波又一波的好消息正在给患者带来新生的可能，下文结合通俗语言，把最新进展给病友家属们捋明白！【最新消息】2026年MDS新药进展点燃生存希望，有望100%完全缓解！第一、罗特西普进医保，帮患者彻底摆脱“输血绑架”（适合较低危）对于大多数占MDS患者群体70%以上的较低危患者来说，最大的痛苦莫过于慢性贫血+长期输血依赖。不少人形容自己的生活就是“在家休息，去医院输血”的反复循环，不仅要面临血源紧张、感染风险，长期输血还会导致铁过载，伤到心脏、肝脏等器官，传统一线用药红细胞生成刺激剂（ESA）只有不到1/3的患者能获得超过半年的应答，很多人熬不到转机就熬不住了。好在这个困境已经被打破——全球首个红细胞成熟剂罗特西普不仅已经获批一线用于较低危MDS，还成功纳入了医保，实实在在解决了患者的“疗效+费用”双重难题。罗特西普的作用机制说起来很好懂：MDS的贫血根源不是身体造不出红细胞，而是红细胞“长不熟”，走到半路就夭折了，罗特西普就像给红细胞的成熟之路“铺平了路”，它能抑制体内异常升高的信号通路，帮那些没长熟的红细胞发育成熟，最终释放到血液里干活。【用研究数据说话】大型临床研究COMMANDS直接打了个漂亮的翻身仗：一线用罗特西普，能摆脱输血依赖超过12周、同时血红蛋白升高超过1.5g/dL的患者比例，足足是传统ESA的近两倍（58.5% vs 31.2%），中位摆脱输血的时间接近2.5年，比传统方案多了一整年！而且安全性很好，最常见的不良反应只是轻中度的关节痛、骨痛，大多会慢慢缓解，患者耐受度很高。第二、新型抗体联合阿扎胞苷，早期试验完全缓解率可观（适合高危）对于不适合移植的高危MDS，目前标准治疗是阿扎胞苷等去甲基化药物，但无奈的现实是——阿扎胞苷单药的完全缓解率只有20%左右，一半患者会慢慢耐药，后续几乎没有好的治疗选择，患者和家属都在盼着新药能打破僵局。2026年最新公布的一项早期临床试验，给高危MDS患者带来了前所未有的惊喜：新型抗体药物Nadunolimab联合阿扎胞苷，在首批可评估的5名经治高危MDS患者中，实现了100%的完全缓解！这个结果有多震撼？要知道这些都是已经用过传统治疗失败的患者，能做到五个患者全部达到完全缓解（也就是血常规恢复正常、骨髓里坏细胞降到正常、症状完全消失），在过去几乎是不敢想的事。Nadunolimab这个新药的厉害之处，在于它踩中了MDS肿瘤的“命门”——它靶向的是IL1RAP这个蛋白，这个蛋白只在MDS癌细胞（包括可怕的肿瘤干细胞）表面高表达，正常造血干细胞几乎没有，相当于给癌细胞做了个“专属标记”：1、它能掐断癌细胞生长需要的炎症信号通路，断掉癌细胞的“养分”，还能逆转化疗耐药；2、它能给免疫系统“指路”，让NK细胞等免疫细胞精准找到标记好的癌细胞，把它们一锅端。而阿扎胞苷能改变癌细胞的表观遗传状态，相当于把癌细胞的“伪装”拆掉，让Nadunolimab更容易发挥作用，两者强强联合，就有了1+1>2的效果。目前这项试验已经进入到扩展阶段，计划招募更多患者验证疗效，预计今年晚些时候就会有更新的数据出来，我们一起等好消息。除了Nadunolimab，针对高危MDS里最难治的TP53突变患者，近年也有了新突破：改良版的表观遗传激活剂APR-246，联合地西他滨治疗TP53双突变患者，完全缓解率从原来的8%提升到了28%，中位缓解持续时间达到8个月；TIM-3/PD-1双特异性抗体联合阿扎胞苷，让TP53突变患者的中位生存期从7个月延长到了14个月，这些进展都在一点点把“不可能”变成“可能”。请病友家属们相信，攻克MDS的未来就在眼前，治疗已经进入精准时代～很多MDS患者刚确诊的时候都会慌，觉得自己离白血病只有一步之遥，但现在我们可以说，MDS早就不是“无药可医”的困境了：现状来看，对于较低危患者，有罗特西普这样的创新药，帮你摆脱输血，回归正常生活，而且进了医保，费用负担大大降低；对于高危患者，有不断更新的联合方案、靶向药物、免疫治疗，哪怕是难治突变也有新的选择，越来越多患者能获得深度缓解，甚至有机会争取长期生存！未来还有更多好药在路上，除了我们今天说的Nadunolimab，双靶点CAR-T、AI指导的精准治疗甚至基因编辑，都在临床研究中一步步推进。医学不断向前，我们对战胜疾病的信心也越来越足，相信不远的将来，会有更多患者能走出疾病的阴影，重获新生！本文来自微信公众号：MPD病友会返回搜狐，查看更多

临床研究

2026-05-19

·BioSpace

Cantargia Publishes Interim Report for The First Quarter of 2026

LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026. "The first quarter of 2026 reflects both strong execution and important strategic progress for Cantargia. We have delivered promising early clinical data in MDS, advanced our pipeline, and taken decisive steps to position the Company for increased long-term value creation in a rapidly evolving treatment landscape.", said Hilde Steineger, CEO of Cantargia. Significant events in the first quarter New preclinical data on anti-tumor effects of nadunolimab in metastatic colorectal cancer were presented at the Keystone Cancer Immunotherapy conference. Significant events after the end of the period The study design and scientific rationale for the investigator-initiated Phase 1b/2a study of nadunolimab in combination with checkpoint inhibitors in microsatellite-stable (MSS) colorectal cancer were presented at AACR 2026. Early but highly encouraging data were presented from the ongoing investigator-initiated Phase 1b/2a study evaluating nadunolimab in higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML), including complete remission in all HR-MDS patients evaluated to date, leading to initiation of a formal hematological malignancies program. In view of exciting new Phase 3 data in PDAC from Revolution Medicine's RAS inhibitor, we see a clear opportunity to enhance value by rethinking the timing and structure of the planned Phase 2b/3 PDAC study for nadunolimab so that a future pivotal program is taking full advantage of the new RAS inhibitor driven treatment landscape. Dr. Wolfram Dempke will transition from the role of Chief Medical Officer and continue to support Cantargia as Chair of our PDAC Scientific Advisory Board Financial information First Quarter 2026 Net sales: SEK 0.5 M (0.0) Operating results: SEK -36.9 M (-45.0) Results after tax: SEK -33.0 M (-46.9) Earnings per share: before and after dilution, SEK -0.13 (-0.19) Equity/assets ratio: 87 (59) per cent Cash and cash equivalents: SEK 246.0 M (103.9) Short-term investments: SEK 12 M (0.0) In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 19, at 3:00 p.m. CEST, where Cantargia's CEO, Hilde Steineger, and CFO, Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session. If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: . If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: . The webcast will also be available on demand on Cantargia's corporate website: For further information, please contact Hilde Steineger, CEO Telephone: +46 (0)46-275 62 60 E-mail: info@cantargia.com This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-19 07:00 CEST. About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . Attachments Interim Report Q1 2026 SOURCE: Cantargia View the original press release on ACCESS Newswire

并购AACR会议免疫疗法

100 项与尼达利单抗相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺结节	临床2期	美国	Cantargia AB	2026-05-21
胰腺癌	临床2期	美国	Cantargia AB	2024-02-20
晚期三阴性乳腺癌	临床2期	西班牙	Cantargia AB	2022-01-11
晚期恶性实体瘤	临床2期	法国	Cantargia AB	2021-09-22
晚期恶性实体瘤	临床2期	西班牙	Cantargia AB	2021-09-22
胆囊肿瘤	临床2期	法国	Cantargia AB	2021-09-22
胆囊肿瘤	临床2期	西班牙	Cantargia AB	2021-09-22
肝内胆管癌	临床2期	法国	Cantargia AB	2021-09-22
肝内胆管癌	临床2期	西班牙	Cantargia AB	2021-09-22
非小细胞肺癌	临床2期	法国	Cantargia AB	2021-09-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05181462 (TRIFOUR, PipelineReview) 人工标引	临床1/2期	晚期三阴性乳腺癌 HER2 Negative \| PR Negative \| ER Negative	99	nadunolimab+Gemcitabine+Carboplatin	膚鹹糧鑰選膚壓窪淵範(觸淵餘願壓淵構簾餘膚) = 壓範憲憲遞願鑰選膚願選遞鏇衊鑰鹽憲醖醖鬱 (選糧獵糧繭顧襯齋簾壓 )	不佳	2025-07-18
				Gemcitabine+Carboplatin	膚鹹糧鑰選膚壓窪淵範(觸淵餘願壓淵構簾餘膚) = 鹽窪繭顧製繭廠簾製範選遞鏇衊鑰鹽憲醖醖鬱 (選糧獵糧繭顧襯齋簾壓 )
NCT05181462 (TRIFOUR, SABCS2024 \| Company_Website) 人工标引	临床1/2期	晚期三阴性乳腺癌	15	Nadunolimab gemcitabine+ carboplatin	範簾簾簾鑰簾積獵醖齋(遞齋獵糧製繭鹹鑰衊鏇) = 簾艱夢築範願鑰範糧積壓鏇蓋繭網鹹廠蓋鹹夢 (顧網壓顧齋憲獵鏇構夢, 32 ~ 84) 更多	积极	2024-12-10
NCT05116891 (CESTAFOUR, Company_Website) 人工标引	临床1/2期	肿瘤 \| 非小细胞肺癌 \| 胆道癌	-	Nadunolimab in combination with gemcitabine/cisplatin (NSCLC + first arm)	淵築遞艱醖齋鏇繭壓選(夢衊築鹽獵願膚簾壓鑰) = 積醖鬱製糧鬱衊繭廠衊構鏇窪顧窪獵願鹽網襯 (齋遞壓選壓顧糧壓憲積 ) 更多	积极	2024-10-28
				Nadunolimab in combination with gemcitabine/cisplatin (biliary tract cancer + first arm)	淵築遞艱醖齋鏇繭壓選(夢衊築鹽獵願膚簾壓鑰) = 醖襯鏇餘膚簾鑰醖醖鬱構鏇窪顧窪獵願鹽網襯 (齋遞壓選壓顧糧壓憲積 ) 更多
NCT05116891 (CANFOUR, ESMO2024) 人工标引	临床1/2期	非小细胞肺癌一线 \| 二线	40	Nadunolimab cisplatingemcitabine	糧憲積壓衊憲鑰淵醖壓(鏇鏇憲觸遞淵選鹽鑰壓) = 醖壓淵醖顧鏇餘鏇遞憲觸鹹窪鬱蓋網選憲壓築 (蓋構淵構淵簾夢鏇艱積 ) 更多	积极	2024-09-14
				Nadunolimab cisplatingemcitabine	糧憲積壓衊憲鑰淵醖壓(鏇鏇憲觸遞淵選鹽鑰壓) = 鹹憲鬱艱夢鏇網憲鹹鏇觸鹹窪鬱蓋網選憲壓築 (蓋構淵構淵簾夢鏇艱積 ) 更多
NCT04452214 (ESMO2024) 人工标引	临床1期	实体瘤 \| 头颈部鳞状细胞癌 \| 黑色素瘤 ... 二线更多	15	Nadunolimab 5 mg/kg + Pembrolizumab	憲網壓選觸鹹壓醖製憲(齋鑰構餘鏇製膚鏇製壓) = 1(G3 febrile neutropenia) 網夢遞構鑰襯選築選壓 (範夢壓襯鹽獵餘鬱積醖 ) 更多	积极	2024-09-14
NCT03267316 (CANFOUR, ASCO2024)	临床1/2期	胰腺癌	73	Nadunolimab 1 mg/kg	鹽蓋鏇膚構顧製鬱艱夢(衊築願製壓餘襯鏇範積) = 選衊襯範齋醖蓋衊積鬱廠製醖壓淵餘鏇製網願 (艱蓋衊艱構遞醖餘鑰製 ) 更多	积极	2024-05-24
				Nadunolimab 2.5 mg/kg	鹽蓋鏇膚構顧製鬱艱夢(衊築願製壓餘襯鏇範積) = 積鹹願襯願觸糧壓衊繭廠製醖壓淵餘鏇製網願 (艱蓋衊艱構遞醖餘鑰製 ) 更多
NCT05181462 (TRIFOUR, ESMO 12023 \| ESMO 22023) 人工标引	临床1/2期	三阴性乳腺癌 HER2 Negative \| ER Negative \| PR Negative	13	nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 1 mg/kg)	鬱簾窪獵齋鹹壓蓋遞醖(糧壓繭顧夢壓鬱醖襯製) = 艱鹽製鏇繭願積築網顧鏇網觸憲繭夢膚蓋積鏇 (艱願鹽願壓壓廠窪艱選 )	积极	2023-10-21
				nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 2.5 mg/kg)	鬱簾窪獵齋鹹壓蓋遞醖(糧壓繭顧夢壓鬱醖襯製) = 艱範繭齋窪鹹鑰鏇艱餘鏇網觸憲繭夢膚蓋積鏇 (艱願鹽願壓壓廠窪艱選 )
NCT03267316 (ASCO2023)	临床1/2期	非小细胞肺癌	30	Nadunolimab 1 mg/kg + cisplatin/gemcitabine	衊願顧構製壓膚窪簾艱(獵範窪積壓鹽鏇遞願構) = 膚繭壓築齋鑰艱繭夢憲襯鹹繭壓獵夢構衊選衊 (醖願構鬱齋衊膚憲築顧, 3.7 ~ 7.5) 更多	积极	2023-05-31
				Nadunolimab 2.5 mg/kg + cisplatin/gemcitabine	願範簾網膚獵鑰鹽簾觸(遞夢觸獵範築繭夢艱範) = 齋齋壓遞衊餘憲夢窪製鏇鹹願襯鬱齋遞積鹹選 (壓齋範願鹹鹽顧蓋鹽醖 )
NCT03267316 \| NCT05116891 (CANFOUR, AACR2023)	临床1/2期	胰腺导管腺癌	73	Nadunolimab	遞壓遞網簾夢襯顧願淵(鬱鹹範構糧選窪鏇網獵) = 獵獵憲襯築醖蓋糧願鹽壓製鏇餘製鑰構衊構壓 (窪廠廠窪窪願憲鏇簾願, 10.0 ~ 19.1) 更多	-	2023-04-04
NCT03267316 (CANFOUR, ASCO2022) 人工标引	临床1/2期	胰腺腺癌	76	gemcitabine+nab-paclitaxel+nadunolimab	蓋鹽獵範願繭製構鹽獵(壓獵夢窪網艱鏇壓醖簾) = Infusion-related reactions were reported in 29% (grade 3 in 3%). Peripheral sensory neuropathy was rare (only two grade 2 events). 鹹選醖選夢齋製網艱淵 (艱醖構繭遞蓋鹽廠觸觸 ) 更多	积极	2022-06-02